WS Audiology delivered 4% organic revenue growth in the first quarter of FY 2024/25

Lynge, Denmark – February 6, 2025 – WS Audiology (WSA), a leading pure play hearing healthcare group, today announced results for the first quarter of the financial year 2024/25 in line with expectations (October 1, 2024 – December 31, 2024).

Jan Makela, CEO of WSA, said:

With an organic revenue growth of 4%, we are off to a good start of the financial year on a high comparative base from last year. Growth continues to be driven by solid performances across all regions and channels, based on our two strong and complementary brand platforms Signia and Widex. We look forward to launching new advanced hearing solutions on both platforms in the coming months, reaffirming our commitment to improving hearing care for all and simplifying the customer journey.

Q1 FY 2024/2025 highlights (Q1 last financial year in brackets)

• WSA delivered organic revenue growth of 4% (13%) to EUR 670 million in line with expectations and driven by continued solid performance across regions and channels based on our two strong and complementary brand platforms Signia and Widex.
• Revenue growth in Q1 last year (13%) was positively impacted by the launch in key markets of our Signia IX platform, which significantly improves users’ ability to participate in noisy group conversations by delivering more than twice the speech enhancement benefit compared to other leading hearing aids[1]. Signia IX continues to be a key growth driver across all regions.
• Revenue growth was broad based with 4% organic growth in all three regions (Americas, EMEA, APAC). Online continued the high growth of previous quarters.
• EBITDA[2] was EUR 114 million corresponding to an EBITDA margin of 17.0% (16.4%) in line with expectations.
• Marianne Vinding Ovesen has joined as Chief Operating Officer, bringing valuable experience from diagnostics and life science from Danaher Corporation, Radiometer and Coloplast to WSA.
• Carsten Buhl, Regional President for WSA Americas, has joined the Executive Board alongside CEO Jan Makela and CFO Marianne Wiinholt, reflecting the importance of the Americas organization in driving profitable growth for WSA in the future.

Financial year 2024/25 outlook

Outlook for the financial year 2024/25 is maintained at 3-6% organic revenue growth supported by our competitive product portfolio and upcoming launches.

The EBITDA margin before special items is expected to increase by 1-2%-points supported by our profitable growth program to drive future margin improvements.

[1] Jensen NS, Wilson C, Kamkar Parsi H, Samra B, Hain J, Best S & Taylor B. 2024. Signia IX delivers more than twice the speech enhancement benefit in a noisy group conversation than the closest competitors. Signia White Paper.

[2] Measured as EBITDA before special items and net of R&D Capex.

About WS Audiology
WS Audiology (WSA) is a leading global pure-play hearing healthcare group, pioneering innovative technologies for over 140 years, helping millions of people with hearing loss regain their hearing, engage in meaningful conversations, and participate fully in society. WSA operates in over 130 markets and employs more than 12,500 people across our innovative brand platforms, Widex and Signia, and a global network of hearing care professionals and consumer-facing businesses. WSA is privately owned by the Tøpholm and Westermann families, the Lundbeck Foundation, and EQT-managed funds. Learn more at www.wsa.com.